...
首页> 外文期刊>BMC Public Health >Treatment outcomes and their determinants in HIV patients on Anti-retroviral Treatment Program in selected health facilities of Kembata and Hadiya zones, Southern Nations, Nationalities and Peoples Region, Ethiopia
【24h】

Treatment outcomes and their determinants in HIV patients on Anti-retroviral Treatment Program in selected health facilities of Kembata and Hadiya zones, Southern Nations, Nationalities and Peoples Region, Ethiopia

机译:在埃塞俄比亚南部民族,民族和人民地区的肯巴塔和哈迪亚地区选定的卫生机构接受抗逆转录病毒治疗计划的艾滋病毒患者的治疗结果及其决定因素

获取原文
           

摘要

Background Ethiopia has been providing free Antiretroviral Treatment (ART) since 2005 for HIV/AIDS patients. ART improves survival time and quality of life of HIV patients but ART treatment outcomes might be affected by several factors. However, factors affecting treatment outcomes are poorly understood in Ethiopia. Hence, this study assesses treatment outcomes and its determinants for HIV patients on ART in selected health facilities of Kembata and Hadiya zones. Methods A retrospective cohort study was conducted on 730 adult HIV/AIDS patients who enrolled antiretroviral therapy from 2007 to 2011 in four selected health facilities of Kembata and Hadiya zones of Southern Ethiopia. Study subjects were sampled from the health facilities based on population proportion to size. Data was ed using data extraction format from medical records. Kaplan-Meier survival function was used to estimate survival probability. Cox proportional hazards regression model was used to identify factors associated with time to death. Result Median age of patients was 32.4?years with Inter Quartile Range (IQR) [15, 65]. The female to male ratio of the study participants’ was 1.4:1. Median CD4 count significantly increased during the last four consecutive years of follow up. A total of 92 (12.6?%) patients died, 106(14.5?%) were lost to follow-up, and 109(15?%) were transferred out. Sixty three (68?%) deaths occurred in the first 6?months of treatment. The median survival time was 25?months with IQR [9, 43]. After adjustment for confounders, WHO clinical stage IV [HR 2.42; 95?% CI, 1.19, 5.86], baseline CD4 lymphocyte counts of 201 cell/mm3 and 350 cell/mm3 [HR 0.20; 95 % CI; 0.09?0.43], poor regimen adherence [HR 2.70 95?% CI: 1.4096, 5.20], baseline hemoglobin level of 10gm/dl and above [HR 0.23; 95?% CI: 0.14, 0.37] and baseline functional status of bedridden [HR 3.40; 95?% CI: 1.61, 7.21] were associated with five year survival of HIV patients on ART. Conclusion All people living with HIV/AIDS should initiate ART as early as possible. Initiation of ART at the early stages of the disease, before deterioration of the functional status of the patients and before the reduction of CD4 counts and hemoglobin levels with an intensified health education on adherence to ART regimen is recommended.
机译:背景技术自2005年以来,埃塞俄比亚一直为艾滋病毒/艾滋病患者提供免费的抗逆转录病毒治疗(ART)。 ART可以提高HIV患者的生存时间和生活质量,但是ART治疗的结果可能会受到多种因素的影响。但是,在埃塞俄比亚对影响治疗结果的因素知之甚少。因此,本研究评估了在Kembata和Hadiya地区选定的医疗机构中接受抗病毒治疗的HIV患者的治疗效果及其决定因素。方法对2007年至2011年在埃塞俄比亚南部肯巴塔和哈迪亚四个选定的卫生机构接受抗逆转录病毒疗法的730名成人HIV / AIDS患者进行回顾性队列研究。根据人口与规模的比例从健康机构中抽取研究对象。使用病历中的数据提取格式编辑数据。 Kaplan-Meier生存函数用于估计生存概率。使用Cox比例风险回归模型来确定与死亡时间相关的因素。结果四分位数间距(IQR)患者的中位年龄为32.4岁[15,65]。研究参与者的男女比例为1.4:1。在过去的连续四年中,CD4计数中位数显着增加。共有92名(12.6%)患者死亡,有106名(14.5%)失访,另有109名(15 %%)被转出。在治疗的前6个月中有63例(68%)死亡。 IQR的中位生存时间为25个月[9,43]。调整混杂因素后,WHO临床分期为IV [HR 2.42; 95%CI,1.19,5.86],基线CD4淋巴细胞计数为201细胞/ mm 3 和350细胞/ mm 3 [HR 0.20; 95%CI; 0.09?0.43],方案依从性差[HR 2.70 95 %% CI:1.4096、5.20],基线血红蛋白水平为10gm / dl及以上[HR 0.23; 95%CI:0.14、0.37]和卧床的基线功能状态[HR 3.40; 95%CI:1.61、7.21]与HIV患者接受ART治疗的5年生存率相关。结论所有艾滋病毒/艾滋病感染者都应尽早开始抗病毒治疗。建议在疾病的早期,在患者功能状态恶化之前以及在CD4计数和血红蛋白水平降低之前开始抗逆转录病毒疗法,并加强对抗逆转录病毒疗法的依从性健康教育。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号